These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 20023039)
1. MEF2 transcriptional activity maintains mitochondrial adaptation in cardiac pressure overload. el Azzouzi H; van Oort RJ; van der Nagel R; Sluiter W; Bergmann MW; De Windt LJ Eur J Heart Fail; 2010 Jan; 12(1):4-12. PubMed ID: 20023039 [TBL] [Abstract][Full Text] [Related]
2. MEF2 activates a genetic program promoting chamber dilation and contractile dysfunction in calcineurin-induced heart failure. van Oort RJ; van Rooij E; Bourajjaj M; Schimmel J; Jansen MA; van der Nagel R; Doevendans PA; Schneider MD; van Echteld CJ; De Windt LJ Circulation; 2006 Jul; 114(4):298-308. PubMed ID: 16847152 [TBL] [Abstract][Full Text] [Related]
3. Modulation of adverse cardiac remodeling by STARS, a mediator of MEF2 signaling and SRF activity. Kuwahara K; Teg Pipes GC; McAnally J; Richardson JA; Hill JA; Bassel-Duby R; Olson EN J Clin Invest; 2007 May; 117(5):1324-34. PubMed ID: 17415416 [TBL] [Abstract][Full Text] [Related]
4. Focal adhesion kinase mediates MEF2 and c-Jun activation by stretch: role in the activation of the cardiac hypertrophic genetic program. Nadruz W; Corat MA; Marin TM; Guimarães Pereira GA; Franchini KG Cardiovasc Res; 2005 Oct; 68(1):87-97. PubMed ID: 15961069 [TBL] [Abstract][Full Text] [Related]
5. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure. Nakamura TY; Iwata Y; Arai Y; Komamura K; Wakabayashi S Circ Res; 2008 Oct; 103(8):891-9. PubMed ID: 18776042 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of cardiac remodeling by pravastatin is associated with amelioration of endoplasmic reticulum stress. Zhao H; Liao Y; Minamino T; Asano Y; Asakura M; Kim J; Asanuma H; Takashima S; Hori M; Kitakaze M Hypertens Res; 2008 Oct; 31(10):1977-87. PubMed ID: 19015605 [TBL] [Abstract][Full Text] [Related]
7. The transcription factor MEF2C mediates cardiomyocyte hypertrophy induced by IGF-1 signaling. Muñoz JP; Collao A; Chiong M; Maldonado C; Adasme T; Carrasco L; Ocaranza P; Bravo R; Gonzalez L; Díaz-Araya G; Hidalgo C; Lavandero S Biochem Biophys Res Commun; 2009 Oct; 388(1):155-60. PubMed ID: 19654000 [TBL] [Abstract][Full Text] [Related]
8. Downregulation of survival signalling pathways and increased apoptosis in the transition of pressure overload-induced cardiac hypertrophy to heart failure. Li XM; Ma YT; Yang YN; Liu F; Chen BD; Han W; Zhang JF; Gao XM Clin Exp Pharmacol Physiol; 2009 Nov; 36(11):1054-61. PubMed ID: 19566828 [TBL] [Abstract][Full Text] [Related]
9. The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. Kim Y; Phan D; van Rooij E; Wang DZ; McAnally J; Qi X; Richardson JA; Hill JA; Bassel-Duby R; Olson EN J Clin Invest; 2008 Jan; 118(1):124-32. PubMed ID: 18079970 [TBL] [Abstract][Full Text] [Related]
10. Gelsolin and cardiac myocyte apoptosis: a new target in the treatment of postinfarction remodeling. Nishio R; Matsumori A Circ Res; 2009 Apr; 104(7):829-31. PubMed ID: 19359605 [No Abstract] [Full Text] [Related]
16. Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model. Janczewski AM; Zahid M; Lemster BH; Frye CS; Gibson G; Higuchi Y; Kranias EG; Feldman AM; McTiernan CF Cardiovasc Res; 2004 Jun; 62(3):468-80. PubMed ID: 15158139 [TBL] [Abstract][Full Text] [Related]
17. Right ventricular failure secondary to chronic overload in congenital heart disease: an experimental model for therapeutic innovation. Lambert V; Capderou A; Le Bret E; Rücker-Martin C; Deroubaix E; Gouadon E; Raymond N; Stos B; Serraf A; Renaud JF J Thorac Cardiovasc Surg; 2010 May; 139(5):1197-204, 1204.e1. PubMed ID: 20412956 [TBL] [Abstract][Full Text] [Related]
18. Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure. Oka T; Akazawa H; Naito AT; Komuro I Circ Res; 2014 Jan; 114(3):565-71. PubMed ID: 24481846 [TBL] [Abstract][Full Text] [Related]
19. Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300. Wei JQ; Shehadeh LA; Mitrani JM; Pessanha M; Slepak TI; Webster KA; Bishopric NH Circulation; 2008 Aug; 118(9):934-46. PubMed ID: 18697823 [TBL] [Abstract][Full Text] [Related]
20. Cardiac steroidogenesis and glucocorticoid in the development of cardiac hypertrophy during the progression to heart failure. Ohtani T; Mano T; Hikoso S; Sakata Y; Nishio M; Takeda Y; Otsu K; Miwa T; Masuyama T; Hori M; Yamamoto K J Hypertens; 2009 May; 27(5):1074-83. PubMed ID: 19349910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]